TheScreener - BANGKOK DUSIT MEDICAL SERVICES PUBLIC CO. LTD. (BDMS) BANGKOK DUSIT MED.SVS. sees an upgrade to Slightly Positive due to a better fundamental star rating

Report

TheScreener

EUR 12.77 For Business Accounts Only

BANGKOK DUSIT MED.SVS. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of BANGKOK DUSIT MED.SVS. (TH), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 18, 2022, the closing price was THB 23.20 and its potential was estimated at THB 24.68.

19/02/2022 1 EN

Underlying

BANGKOK DUSIT MEDICAL SERVICES PUBLIC CO. LTD.

Bangkok Dusit Medical Services Public Company Limited is a Thailand-based company engaged in hospital business. The Company and its subsidiaries operate two business segments, which consist of hospital operations and other businesses that support hospital business, including central lab services, the manufacture and distribution of medicine and pharmaceutical products, assets management for healthcare business, restaurants and distribution of health food products, facility management, technology and information services, accounting services, training business, health insurance and life insurance brokerage. Its subsidiaries comprise Samitivej PCL., Bangkok Hospital Hatyai Co., Ltd., Bangkok Phuket Hospital Co., Ltd., BNH Medical Center Co., Ltd., Bangkok Phrapradaeng Hospital Co., Ltd., Bangkok Pattaya Hospital Co., Ltd., Bangkok Rayong Hospital Co., Ltd. and Bangkok Samui Hospital Co., Ltd., among others.

See profile

TH0264A10Z04 Stock Exchange of Thailand Thailand

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

UOB

Bangkok Dusit Medical Services (BDMS TB) - Expect Mild Earnings Growth In 2Q25

We expect BDMS to report a net profit of Bt3.4b in 2Q25 (+2.1% yoy). The top-line should be at Bt26.9b (+4.7% yoy, -4.2% qoq), with main contributions from a modest revenue growth from Thai patients and a robust growth from foreign patient arrivals especially due to a strong rebound in Middle East patient arrivals. The latest Thai-Cambodia conflict is causing some slowdown in Cambodian patient arrivals, but we expect it to be only a short-term issue. Maintain BUY. Target price: Bt32.00.

July 16, 2025 July 16, 2025 1 EN

UOB

Thailand Daily - Wednesday, July 16 , 2025

KEY HIGHLIGHTS Results TISCO Financial Group (TISCO TB/HOLD/Bt99.00/Target: Bt96.00) 2Q25: Results in line with consensus; impact from "You Fight We Help" measure should be mostly reflected. Update Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.60/Target: Bt32.00) Expect mild 2Q25 earnings growth. SCGP (SCGP TB/BUY/Bt17.30/Target: Bt21.00) 2Q25 net profit expected to recover qoq, with 2H25 net profit likely to surpass 1H25.

July 16, 2025 July 16, 2025 1 EN

UOB

Regional Morning Meeting Notes: Wednesday, July 16, 2025

GREATER CHINA Economics Economic Activity Resilient 1H25 growth of 5.3% yoy belies rising downside pressure. Sector Healthcare Weekly: Gaining strength on robust earnings outlook and pipeline growth. Maintain OVERWEIGHT. Property Property sales and prices weakened further in June and July; CUWC set a pragmatic tone without any mention of large-scale urban redevelopment. Upda...

July 16, 2025 July 16, 2025 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BANGKOK DUSIT MED.SVS. sees an upgrade to Slightly Positive due to a better fundamental star rating

Empowering Investors

Bangkok Dusit Medical Services (BDMS TB) - Expect Mild Earnings Growth In 2Q25

Thailand Daily - Wednesday, July 16 , 2025

Regional Morning Meeting Notes: Wednesday, July 16, 2025

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe